StreetInsider.com News Articles

Stifel Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

Mon, 15 Jun 2026 09:32:46 -0400

Stifel analyst Stephen Willey reiterated a Buy rating and $46.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).

The analyst commented, "The breadth of revumenib data presented at EHA – including a combination of prospectivelygenerated data in relapsed/refractory (SAVE) and 1L (SNDX-5613-0708) AML, real-world data (ROAR), and multiple retrospective analyses highlighting outcomes across disease-specific subtypes and patient-specific subgroups – highlights SNDX’s leadership position in the menin inhibitor space and its broader strategy of driving continued utilization through the generation and presentation/publication of data intended to increase physician familiarity and expand potential treatment guideline inclusion opportunities. We believe increasingly consistent revumenib activity in

Form 4 Syndax Pharmaceuticals For: Jun 11 Filed by: Botwood Nicholas A.J.

Fri, 12 Jun 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260612/26642009.html

Form 4 Syndax Pharmaceuticals For: Jun 11 Filed by: Botwood Nicholas A.J.

Fri, 12 Jun 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260612/26642009.html

Form 144 Syndax Pharmaceuticals Filed by: Botwood Nicholas A.J.

Fri, 12 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260612/26640857.html

Form 144 Syndax Pharmaceuticals Filed by: Botwood Nicholas A.J.

Fri, 12 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260612/26640857.html

Syndax Pharmaceuticals (SNDX) PT Lowered to $31 at Guggenheim

Fri, 12 Jun 2026 06:54:46 -0400

Guggenheim analyst Bradley Canino lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $31.00 (from $34.00) while maintaining a Buy rating.

H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

Fri, 12 Jun 2026 06:53:06 -0400

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $40.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).

The analyst commented: "Yesterday, Syndax’s EHA 2026 updates substantiated that Revuforj is on a clear trajectory toward frontline integration, utility in post-HSCT maintenance, and has real-world success beyond the clinical trial setting. Here, we put our hematologic prowess to the test and provide a deep dive into the data starting on page 3 of this report. Phase 1 data evaluating Revuforj combined with intensive chemotherapy in newly diagnosed AML provided credibility in the frontline and de-risks the combinatorial approach ahead of the Phase

Form 144 Syndax Pharmaceuticals Filed by: Botwood Nicholas A.J.

Thu, 11 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260611/26635775.html

Form 144 Syndax Pharmaceuticals Filed by: Botwood Nicholas A.J.

Thu, 11 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260611/26635775.html

Syndax presents Revuforj clinical data across acute leukemia subtypes

Thu, 11 Jun 2026 07:03:36 -0400

Syndax Pharmaceuticals (NASDAQ: SNDX) presented clinical data for Revuforj (revumenib) across multiple acute leukemia subtypes at the European Hematology Association 2026 Congress. The company submitted 12 abstracts focused on the FDA-approved menin inhibitor.

A real-world study called ROAR showed an 82% overall response rate and 64% complete remission rate among 11 patients with relapsed/refractory NPM1 mutated or KMT2A-rearranged acute leukemia treated with revumenib monotherapy or combinations.

In a Phase 1 trial combining revumenib with intensive chemotherapy for newly diagnosed patients, 97% achieved composite complete remission and 86% showed measurable residual disease negativity among responders. The trial included 35 patients with NPM1 mutated

Syndax presents Revuforj clinical data across acute leukemia subtypes

Thu, 11 Jun 2026 07:03:36 -0400

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

Thu, 11 Jun 2026 07:03:00 -0400

– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations –

– Ph 1 trial of revumenib with intensive chemotherapy in newly diagnosed NPM1m or KMT2Ar AML shows 97% (34/35) CRc and 86% (25/29) MRD negativity among CRc responders –

– Post-hoc analysis of patients with R/R NPM1m, KMT2Ar, or NUP98r acute leukemia in the AUGMENT-101 trial who resumed revumenib post-HSCT shows an observed 1-year OS of 95% –

– Phase 1 trial and expanded access experience shows 28% (7/25) ORR

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

Thu, 11 Jun 2026 07:03:00 -0400

– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations –

– Ph 1 trial of revumenib with intensive chemotherapy in newly diagnosed NPM1m or KMT2Ar AML shows 97% (34/35) CRc and 86% (25/29) MRD negativity among CRc responders –

– Post-hoc analysis of patients with R/R NPM1m, KMT2Ar, or NUP98r acute leukemia in the AUGMENT-101 trial who resumed revumenib post-HSCT shows an observed 1-year OS of 95% –

– Phase 1 trial and expanded access experience shows 28% (7/25) ORR

Syndax publishes SAVE trial data on Revuforj combination therapy in AML

Thu, 11 Jun 2026 07:02:18 -0400

Syndax Pharmaceuticals (NASDAQ: SNDX) announced that data from its SAVE trial studying an oral combination of Revuforj (revumenib), decitabine/cedazuridine, and venetoclax in relapsed/refractory acute myeloid leukemia patients was published in the Journal of Clinical Oncology.
The Phase 1/2 trial enrolled 42 patients with relapsed or refractory AML containing NPM1 mutations, KMT2A rearrangements, or NUP98 rearrangements. Patients had a median age of 40 years and received a median of two prior lines of therapy. The study reported an overall response rate of 88%, with 71% achieving composite complete remission and 60% achieving complete remission or complete remission with partial hematological recovery.
Among patients

Syndax publishes SAVE trial data on Revuforj combination therapy in AML

Thu, 11 Jun 2026 07:02:18 -0400

Syndax Pharmaceuticals (NASDAQ: SNDX) announced that data from its SAVE trial studying an oral combination of Revuforj (revumenib), decitabine/cedazuridine, and venetoclax in relapsed/refractory acute myeloid leukemia patients was published in the Journal of Clinical Oncology.
The Phase 1/2 trial enrolled 42 patients with relapsed or refractory AML containing NPM1 mutations, KMT2A rearrangements, or NUP98 rearrangements. Patients had a median age of 40 years and received a median of two prior lines of therapy. The study reported an overall response rate of 88%, with 71% achieving composite complete remission and 60% achieving complete remission or complete remission with partial hematological recovery.
Among patients

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Cl

Thu, 11 Jun 2026 07:00:00 -0400

– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) –

– Strong activity across subgroups, including 70% (14/20) CR/CRh in venetoclax-naïve and 50% (11/22) CR/CRh in venetoclax-exposed patients –

– Deep responses with 80% (24/30) MRD negativity among evaluable CRc responders –

– Robust transplant rate with 45% (19/42) of patients proceeding to transplant and 63% (12/19) resuming revumenib post-transplant –

– Encouraging durability with median overall survival after transplant not reached –

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Cl

Thu, 11 Jun 2026 07:00:00 -0400

– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) –

– Strong activity across subgroups, including 70% (14/20) CR/CRh in venetoclax-naïve and 50% (11/22) CR/CRh in venetoclax-exposed patients –

– Deep responses with 80% (24/30) MRD negativity among evaluable CRc responders –

– Robust transplant rate with 45% (19/42) of patients proceeding to transplant and 63% (12/19) resuming revumenib post-transplant –

– Encouraging durability with median overall survival after transplant not reached –

Syndax raises $250 million through convertible notes offering

Wed, 10 Jun 2026 17:08:42 -0400

Syndax Pharmaceuticals (NASDAQ: SNDX) completed a private placement of $250 million in convertible senior notes on June 10, according to a company filing. The 2.25% convertible senior notes are due in 2031.
The pharmaceutical company received net proceeds of approximately $243 million after deducting placement agent fees and offering expenses. Syndax stated it plans to use the funds for general corporate purposes, including working capital, research and development, commercialization activities, and business development.
The notes were issued under an indenture with U.S. Bank Trust Company, National Association serving as trustee. The offering was conducted through privately negotiated subscription agreements dated June 3.
The

Syndax raises $250 million through convertible notes offering

Wed, 10 Jun 2026 17:08:42 -0400

Syndax Pharmaceuticals (NASDAQ: SNDX) completed a private placement of $250 million in convertible senior notes on June 10, according to a company filing. The 2.25% convertible senior notes are due in 2031.
The pharmaceutical company received net proceeds of approximately $243 million after deducting placement agent fees and offering expenses. Syndax stated it plans to use the funds for general corporate purposes, including working capital, research and development, commercialization activities, and business development.
The notes were issued under an indenture with U.S. Bank Trust Company, National Association serving as trustee. The offering was conducted through privately negotiated subscription agreements dated June 3.
The

Form 8-K Syndax Pharmaceuticals For: Jun 10

Wed, 10 Jun 2026 17:05:00 -0400
si-local-file:///var/storage/secattach/20260610/26630764.html

Form 8-K Syndax Pharmaceuticals For: Jun 10

Wed, 10 Jun 2026 17:05:00 -0400
si-local-file:///var/storage/secattach/20260610/26630764.html

Form 8-K Syndax Pharmaceuticals For: Jun 10

Wed, 10 Jun 2026 16:16:00 -0400
si-local-file:///var/storage/secattach/20260610/26630075.html

Form 8-K Syndax Pharmaceuticals For: Jun 10

Wed, 10 Jun 2026 16:16:00 -0400
si-local-file:///var/storage/secattach/20260610/26630075.html

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Thu, 04 Jun 2026 16:01:00 -0400

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2026, the Company granted inducement awards to purchase up to 66,700 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Thu, 04 Jun 2026 16:01:00 -0400

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2026, the Company granted inducement awards to purchase up to 66,700 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through